Management of L-asparaginase induced prothrombotic state in acute lymphoblastic leukemia.

in their report Inefficacy of fresh frozen plasma in the treatment of L-asparaginase induced coagulation factor deficiencies during ALL induction therapy, Nowak-Göttl and coll. reported that the prophylactic administration of fresh frozen plasma in acute lymphoblastic leukemia (ALL) patients treated with L-asparaginase (L-Ase) is of no use in correcting the hemostatic imbalance. In fact, they observed no increase in antithrombin III (ATIII) or plasminogen levels, and only a minimal increase in thrombin and a2-antiplasmin levels. It has been established that L-Ase used in ALL patients can induce thrombotic events by reducing coagulation inhibitors (ATIII, protein C and protein S) and inducing endothelial damage. We wish to report our experience in the prevention of coagulation disorders induced by L-Ase therapy in adult ALL patients. As suggested by some authors, we administered ATIII concentrates during L-Ase therapy to restore hemostasis altered by chemotherapy. In these patients, and in a control group of non-supported patients, we studied two hypercoagulability markers: the thrombin-antithrombin complex (TAT) and Ddimer. Our study confirms that L-Ase treatment can induce a hypercoagulability state which can be corrected by the administration of ATIII concentrates. In fact, in the ATIII supported group TAT and D-dimer levels returned to normal, while the same hypercoagulability markers increased in the control group, who experienced some thrombotic events. The administration of ATIII concentrates alone cannot restore hemostasis, but may be important in regulating the prothrombotic state related to possible endothelial injury. Our study suggests that ATIII concentrates are more suitable than fresh frozen plasma infusion for normalizing the prothrombotic state. In our Department, prophylactic administration of ATIII concentrates is currently performed in all ALL patients treated with L-Ase. We have not observed thrombotic events in any of the thirty patients treated so far.